IFF Full-Year Report 2023

  • Reported net sales for the fourth quarter were $2.70 billion, a decrease of 5% compared to the prior year period. On a comparable basis, currency neutral sales increased 1% versus the prior year period, led by growth in Scent and Health & Biosciences. Volume performance continued to improve sequentially across nearly all businesses and pricing remained solid.
  • Loss before taxes on a reported basis for the fourth quarter was $2.64 billion, largely driven by a non-cash goodwill impairment charge of $2.6 billion. Adjusted operating EBITDA for the fourth quarter was $461 million. On a comparable basis, currency neutral adjusted operating EBITDA increased 17% led by favorable net pricing and productivity gains.
  • Reported earnings (loss) per share (EPS) for the fourth quarter was $(10.21). Adjusted EPS excluding amortization was $0.72 per diluted share.
  • Cash flow from operations for the full year was $1.44 billion, and free cash flow defined as cash flow from operations less capital expenditures totaled $936 million. Total debt to trailing twelve months net loss at the end of the fourth quarter was (3.9)x. Net debt to credit-adjusted EBITDA at the end of the fourth quarter was 4.5x.

Free Trial

Step 1 of 2

This field is for validation purposes and should be left unchanged.
Name(Required)

By pressing “Send” you agree to the Privacy Policy of this site

No Credit Card needed, after filling up the form you will receive your Free-Trial login information in 24 to 48 hours by e-mail.

ImprintPrivacy Policy

All Rights Reserved © aicorite.com